Cooley LLP announced today that it advised Jazz Pharmaceuticals plc (NASDAQ: JAZZ) in a recent $314.4 million public offering of its ordinary shares by certain of Jazz Pharmaceutical’s existing shareholders, including entities affiliated with Kohlberg Kravis Roberts, Longitude Capital Partners and Beecken Petty O’Keefe & Company. Jazz Pharmaceuticals, a long-time Cooley client, is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company, which is headquartered in Dublin, Ireland with multiple offices in the United States, the United Kingdom and other countries in Europe, has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.
The Cooley securities team that advised Jazz Pharmaceuticals was led by partners Chad Mills and Charlie Kim and included associates Matthew Dubofsky, Christine Liu and Michael Wu. Tax advice was provided by partners Mark Windfeld-Hansen and Mark Hrenya; regulatory advice was provided by partners Natasha Leskovsek and Drew Gantt; and intellectual property advice was provided by partners Bill Christiansen and Erich Veitenheimer.
